Welcome to our dedicated page for MYRIAD GENETICS SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MYRIAD GENETICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MYRIAD GENETICS's regulatory disclosures and financial reporting.
Newcomer Lee Nisley reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics director Lee Nisley Newcomer received a grant of restricted stock units. The Form 4 shows an award of 59,701 shares of common stock-equivalent units at no purchase price under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan.
Each restricted stock unit represents one share of Myriad Genetics common stock and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. After this award, Newcomer directly holds 191,842 shares or share-equivalent units in total.
Davis Mark Steven reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics director Mark Steven Davis received a grant of 59,701 restricted stock units (RSUs) of common stock. The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan and carries no purchase price.
Each RSU represents a right to receive one Myriad Genetics common share and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Davis directly holds 106,665 shares of common stock, reflecting his updated ownership position.
Phanstiel S. Louise reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics Inc. director S. Louise Phanstiel received an equity award of 59,701 restricted stock units (RSUs). The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan at no cash cost to the director.
Each RSU represents a contingent right to receive one share of Myriad Genetics common stock and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Phanstiel directly holds 341,652 shares of common stock, reflecting her updated ownership position including the new award.
Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Heinrich Dreismann received a grant of 59,701 restricted stock units of common stock. The award was made at no cash cost per share and is part of the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a right to receive one common share and will vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Following this equity award, Dreismann directly holds 231,145 shares of Myriad Genetics common stock.
Reitan Colleen F reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Colleen F. Reitan received an equity grant of 59,701 shares of common stock in the form of restricted stock units under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Following this award, she directly holds 152,030 shares of common stock.
Each restricted stock unit represents a right to receive one share of common stock and will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant. This is a compensation-related award rather than an open-market share purchase.
Bisaro Paul reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Paul Bisaro received an equity award in the form of 59,701 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents a right to one share and will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. After this grant, Bisaro directly holds 157,142 shares of common stock.
Kumar Rashmi reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Rashmi Kumar received an equity grant of 59,701 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash cost and bring Kumar’s direct holdings to 186,889 shares. Each RSU represents a contingent right to receive one share of common stock and will vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting.
Myriad Genetics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Amended and Restated 2012 Employee Stock Purchase Plan, increasing the shares authorized for issuance under the plan by an additional 4,000,000 shares.
They also approved the 2026 Employee, Director and Consultant Equity Incentive Plan, which provides for 6,400,000 shares of common stock plus 2,063,567 shares rolled over from the 2017 plan, for a total of 8,463,567 shares, with the reserve potentially rising to a maximum of 8,659,575 shares as prior awards lapse. Three Class III directors were elected to terms expiring at the 2029 annual meeting, Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026, and an advisory vote approved named executive officer compensation. A quorum of 77,758,631 shares, representing approximately 82.33% of the 94,443,029 shares outstanding as of the April 8, 2026 record date, was present or represented.
Jampa Raj reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC Chief Technology Officer Raj Jampa received an equity grant of 251,889 restricted stock units. The award has no cash purchase price and represents a contingent right to receive an equal number of common shares. According to the terms, the units vest in four equal annual installments beginning on the first anniversary of the grant date, aligning the CTO’s compensation with long-term company performance.
MYRIAD GENETICS INC filed an initial ownership report for Raj Jampa, who serves as Chief Technology Officer. This Form 3 filing lists him as an officer but does not show any stock or option transactions, so it simply establishes his status as an insider for future reporting.